GlassScriptPhysician profile
Todd A Hayes
NPI 1770604233
$1,710.54
in general payments reported to CMS, 2019-2025
30 companies · $86.66 in 2025
The $86.66 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $300 · 2021: $126 · 2022: $124 · 2023: $180 · 2024: $14.58 · 2025: $86.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $387.17 | 2019-2020 | |
| Abbvie INC. | $286.23 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $172.93 | 2019-2020 | |
| Biogen, INC. | $138.76 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $80.87 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $68.58 | 2019 | |
| Neurelis, INC. | $45.75 | 2021-2023 | Valtoco |
| Grifols USA, LLC | $43.98 | 2022-2025 | Gamunex-C |
| Lilly USA, LLC | $42.23 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $38.64 | 2019-2020 | |
| Acorda Therapeutics, INC | $35.94 | 2019-2020 | |
| Ge Healthcare | $34.64 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $33.29 | 2019 | |
| Amgen INC. | $31.39 | 2019 | |
| Lundbeck LLC | $28.47 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $27.94 | 2019 | |
| Genzyme Corporation | $23.95 | 2019 | |
| Neurocrine Biosciences, INC. | $18.73 | 2019 | |
| Eisai INC. | $17.47 | 2019 | |
| Saol Therapeutics INC. | $17.22 | 2019 | |
| Emd Serono, INC. | $15.69 | 2020 | |
| Bausch Health US, LLC | $15.19 | 2020 | |
| Acadia Pharmaceuticals INC | $15.16 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.58 | 2024 | Dysport |
| Assertio Therapeutics, INC. | $13.75 | 2019 | |
| Greenwich Biosciences, INC. | $13.11 | 2019 | |
| Ucb, INC. | $12.71 | 2019 | |
| Sumitomo Pharma America, INC. | $12.57 | 2023 | Aptiom |
| Adamas Pharmaceuticals, INC. | $11.87 | 2019 | |
| Argenx US, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.